Loren Becker

Loren Becker supports clients in navigating US and global policy and market access issues, with a focus on vaccines and emerging infectious threats.

Prior to joining Avalere, Loren spent nearly 15 years working with a broad network of global health stakeholders to address policy, regulatory, and market-based issues affecting development of and access to vaccines and other health technologies. In roles with Gavi, The Vaccine Alliance, the Coalition for Epidemic Preparedness Innovations, and a variety of product developers, she has built and managed partnerships, strategies, and programs to ensure that patients and communities have access to life-saving innovation. Loren brings expertise and experience in R&D-enabling policies and incentives, global regulatory pathways, global epidemic preparedness, and cross-sector partnership.

Loren has an MPP with a health policy certificate and global concentration from Duke University and a BA in Latin American studies from the George Washington University.

Authored Content

The COVID-19 pandemic response has increased investment in vaccine innovations, but also exposed gaps in US and global vaccine access and delivery.

In 2020, the COVID-19 pandemic resulted in nationwide lockdowns and restrictions with a well-documented impact on utilization of routine healthcare services.

On May 5, the Biden administration announced its support for waiving World Trade Organization (WTO) intellectual property regulations with respect to COVID-19 vaccines, in an effort to increase supply and worldwide access to the vaccines.

On January 21, the Biden administration released its National Strategy for the COVID-19 Response and Pandemic Preparedness. The plan highlights numerous actions that the administration intends to implement as it assumes responsibility in the fight against COVID-19.

Join Avalere’s panel of policy, public health, and regulatory experts to learn about the challenges, opportunities, and key milestones to watch.

Globally and in the US, widespread vaccination has demonstrated medical, economic, and social value to both individuals and public health and has contributed to reductions in morbidity and mortality of certain diseases.

As the pipeline of novel vaccines expands, so does the pipeline for other “vaccine-like” products.

On April 15, President Trump announced his intention to halt funding to the World Health Organization (WHO), pending an investigation into WHO’s response to the COVID-19 pandemic. WHO first declared the outbreak a Public Health Emergency of International Concern on January 30 and a global pandemic on March 11. A reduction in funding from the US could limit WHO’s COVID-19 response activities as well as its regular vaccine programming, including product prequalification, global surveillance, and ongoing efforts to strengthen health systems.

Although influenza disease burden is high, vaccine uptake remains low.

Nearly 80,000 people died during the 2017–2018 influenza season. Only 37% of adults were vaccinated. Several novel emerging products could make vaccination more accessible and effective, potentially reshaping the market and lowering influenza disease burden.

New research shows higher cost sharing for vaccines under Part D leads to fewer seniors getting vaccines. Immunization rates are higher for vaccines covered by Part D plans with lower cost sharing.